Celldex Therapeutics Inc (CLDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has a cash flow conversion efficiency ratio of -0.144x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.59 Million) by net assets ($456.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CLDX net asset quality index to measure how much of total assets are equity-financed.
Celldex Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1986–2025)
This chart illustrates how Celldex Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Celldex Therapeutics Inc (CLDX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Celldex Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celldex Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TIME Dotcom Bhd
KLSE:5031
|
0.104x |
|
BlackBerry Ltd
TO:BB
|
0.025x |
|
Jiangxi Hongdu Aviation Industry Co Ltd
SHG:600316
|
0.092x |
|
Transmissora Aliança de Energia Elétrica S.A
SA:TAEE11
|
0.086x |
|
NCsoft Corp
KO:036570
|
0.009x |
|
Aura Minerals Inc
TO:ORA
|
0.571x |
|
BKV Corporation
NYSE:BKV
|
0.034x |
|
Cal-Comp Electronics (Thailand) Public Company Limited
TW:9105
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Celldex Therapeutics Inc (1986–2025)
The table below shows the annual cash flow conversion efficiency of Celldex Therapeutics Inc from 1986 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Celldex Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $527.16 Million | $-210.94 Million | -0.400x | -89.45% |
| 2024-12-31 | $747.00 Million | $-157.78 Million | -0.211x | +15.51% |
| 2023-12-31 | $429.17 Million | $-107.29 Million | -0.250x | +21.38% |
| 2022-12-31 | $326.20 Million | $-103.73 Million | -0.318x | -119.00% |
| 2021-12-31 | $419.48 Million | $-60.91 Million | -0.145x | +24.76% |
| 2020-12-31 | $209.36 Million | $-40.40 Million | -0.193x | +60.90% |
| 2019-12-31 | $94.03 Million | $-46.41 Million | -0.494x | +18.60% |
| 2018-12-31 | $124.06 Million | $-75.23 Million | -0.606x | -43.44% |
| 2017-12-31 | $236.37 Million | $-99.93 Million | -0.423x | +0.72% |
| 2016-12-31 | $265.43 Million | $-113.04 Million | -0.426x | -24.93% |
| 2015-12-31 | $290.11 Million | $-98.89 Million | -0.341x | +28.94% |
| 2014-12-31 | $211.66 Million | $-101.54 Million | -0.480x | -126.71% |
| 2013-12-31 | $319.80 Million | $-67.67 Million | -0.212x | +59.29% |
| 2012-12-31 | $95.77 Million | $-49.78 Million | -0.520x | -0.18% |
| 2011-12-31 | $68.72 Million | $-35.66 Million | -0.519x | -28.57% |
| 2010-12-31 | $75.25 Million | $-30.37 Million | -0.404x | +0.33% |
| 2009-12-31 | $73.77 Million | $-29.87 Million | -0.405x | -140.17% |
| 2008-12-31 | $18.13 Million | $18.28 Million | 1.008x | -0.54% |
| 2007-12-31 | $-19.04 Million | $-19.30 Million | 1.014x | -91.89% |
| 2006-12-31 | $2.16 Million | $27.00 Million | 12.494x | +4437.96% |
| 2005-12-31 | $20.89 Million | $-6.02 Million | -0.288x | -6.91% |
| 2004-12-31 | $38.41 Million | $-10.35 Million | -0.269x | +35.92% |
| 2003-12-31 | $27.92 Million | $-11.74 Million | -0.420x | +20.89% |
| 2002-12-31 | $31.34 Million | $-16.66 Million | -0.531x | -15.53% |
| 2001-12-31 | $45.27 Million | $-20.83 Million | -0.460x | -459.83% |
| 2000-12-31 | $53.93 Million | $-4.43 Million | -0.082x | +83.24% |
| 1999-12-31 | $17.41 Million | $-8.54 Million | -0.490x | -3.59% |
| 1998-12-31 | $18.80 Million | $-8.90 Million | -0.473x | +61.27% |
| 1997-12-31 | $6.30 Million | $-7.70 Million | -1.222x | -96.56% |
| 1996-12-31 | $15.60 Million | $-9.70 Million | -0.622x | -25.93% |
| 1995-12-31 | $16.00 Million | $-7.90 Million | -0.494x | +4.51% |
| 1994-12-31 | $17.60 Million | $-9.10 Million | -0.517x | -173.56% |
| 1993-12-31 | $29.10 Million | $-5.50 Million | -0.189x | +3.08% |
| 1992-12-31 | $20.00 Million | $-3.90 Million | -0.195x | +32.40% |
| 1991-12-31 | $10.40 Million | $-3.00 Million | -0.288x | 0.00% |
| 1990-12-31 | $10.40 Million | $-3.00 Million | -0.288x | -439.84% |
| 1989-12-31 | $13.10 Million | $-700.00K | -0.053x | +35.88% |
| 1988-12-31 | $8.40 Million | $-700.00K | -0.083x | -107.05% |
| 1986-12-31 | $10.40 Million | $12.30 Million | 1.183x | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more